Proteína moduladora de la actividad del receptor de aril hidrocarburos (AIP): genética, bioquímica e impacto clínico

Aryl hydrocarbon receptor interacting protein (AIP): genetics, biochemistry and clinical impact

Contenido principal del artículo

Andres Florez Romero
William Rojas
Carlos Reverend L.
Lilian Torres
Gloria Quintero

Resumen

El gen AIP (proteína moduladora de la actividad del receptor de aril hidrocarburos) se localiza en la región 11q13.2 y codifica para una proteína de 330 aminoácidos que interactúa con el factor de transcripción AhR (receptor para aril hidrocarburos). Las mutaciones en este gen se han asociado con adenomas pituitarios aislados de tipo familiar (APAF). Se caracterizan por una presentación temprana (alrededor de 20 años), por lo regular producen hormona de crecimiento y/o prolactina, tienen un comportamiento clínico agresivo y poca respuesta a análogos de somatostatina.

Palabras clave:

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Biografía del autor/a

Andres Florez Romero , Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Medina Interna, Endocrinólogía. Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

William Rojas , Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Servicio de Endocrinología, Hospital de San José. Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Carlos Reverend L. , Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Grupo de Ciencias Básicas en Salud. Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Lilian Torres , Fundación Universitaria de Ciencias de la Salud

Grupo de Ciencias Básicas en Salud. Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Gloria Quintero , Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Medicina Interna. Fundación Universitaria de Ciencias de la Salud. Bogotá DC, Colombia.

Referencias

Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228-30. doi: 10.1126/science.1126100

Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain- Rea ML, Barlier A, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373-83. doi: 10.1210/jc.2009-2556

Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013;34(2):239-77. doi: 10.1210/er.2012-1013

AIP Gene (Protein Coding). Aryl Hydrocarbon Receptor Interacting Protein [Internet]. The GeneCards human gene database; [citado 2019 enero]; Recuperado de: https://www.genecards.org/cgi-bin/ carddisp.pl?gene=AIP.

Exon Structure for AIP [Internet]. GeneLoc Genome Locator; [citado 2019 enero]; Recuperado de: https://genecards.weizmann. ac.il/geneloc-bin/exon_struct.pl?disp_name=AIP&chr_nr=11)..

Gadelha MR, Trivellin G, Hernández Ramírez LC, Korbonits M. Genetics of pituitary adenomas. Front Horm Res. 2013;41:111-40. doi: 10.1159/000345673

Hernández-Ramírez LC, Martucci F, Morgan RM, Trivellin G, Tilley D, Ramos-Guajardo N, et al. Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations. J Clin Endocrinol Metab. 2016;101(8):3144-54. doi: 10.1210/jc.2016- 1307

Lecoq AL, Viengchareun S, Hage M, Bouligand J, Young J, Boutron A, et al. AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocr Relat Cancer. 2016;23(5):433-43. doi: 10.1530/ERC-16-0041

Tuominen I, Heliövaara E, Raitila A, Rautiainen MR, Mehine M, Katainen R, et al. AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling. Oncogene. 2015;34(9):1174-84. doi: 10.1038/onc.2014.50

Hernández-Ramírez LC, Trivellin G, Stratakis CA. Role of Phosphodiesterases on the Function of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) in the Pituitary Gland and on the Evaluation of AIP Gene Variants. Horm Metab Res. 2017;49(4):286-95. doi: 10.1055/s-0043-104700

Trivellin G, Korbonits M. AIP and its interacting partners. J Endocrinol. 2011;210(2):137-55. doi: 10.1530/JOE-11-0054

Lloyd C, Grossman A. The AIP (aryl hydrocarbon receptor- interacting protein) gene and its relation to the pathogenesis of pituitary adenomas. Endocrine. 2014;46(3):387-96. doi: 10.1007/ s12020-013-0125-6

Fajardo-Montañana C, Daly AF, Riesgo-Suárez P, Gómez-Vela J, Tichomirowa MA, Camara-Gómez R, et al. [AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature]. Endocrinol Nutr. 2009;56(7):369-77. doi: 10.1016/S1575-0922(09)72456-8

Cannavo S, Trimarchi F, Ferraù F. Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden. Mol Cell Endocrinol. 2017;457:81-8. doi: 10.1016/j. mce.2016.12.019

Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-27. doi: 10.1016/j.tem.2010.02.007

Formosa R, Xuereb-Anastasi A, Vassallo J. Aip regulates cAMP signalling and GH secretion in GH3 cells. Endocr Relat Cancer. 2013;20(4):495-505. doi: 10.1530/ERC-13-0043

Raitila A, Lehtonen HJ, Arola J, Heliövaara E, Ahlsten M, Georgitsi M, et al. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am J Pathol. 2010;177(4):1969-76. doi: 10.2353/ajpath.2010.100138

Goldfarb SB, Kashlan OB, Watkins JN, Suaud L, Yan W, Kleyman TR, et al. Differential effects of Hsc70 and Hsp70 on the intracellular trafficking and functional expression of epithelial sodium channels. Proc Natl Acad Sci U S A. 2006;103(15):5817-22. doi: 10.1073/pnas.0507903103

Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010;31(8):950-60. doi: 10.1002/humu.21292

Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab. 2007;92(5):1952-5. doi: 10.1210/jc.2006-2702

Formosa R, Vassallo J. Aryl Hydrocarbon Receptor-Interacting Protein (AIP) N-Terminus Gene Mutations Identified in Pituitary Adenoma Patients Alter Protein Stability and Function. Horm Cancer. 2017;8(3):174-84. doi: 10.1007/s12672-017-0288-3

Rostomyan L, Potorac I, Beckers P, Daly AF, Beckers A. AIP mutations and gigantism. Ann Endocrinol (Paris). 2017;78(2):123- 30. doi: 10.1016/j.ando.2017.04.012

Korbonits M, Storr H, Kumar AV. Familial pituitary adenomas - who should be tested for AIP mutations? Clin Endocrinol (Oxf). 2012;77(3):351-6. doi: 10.1111/j.1365-2265.2012.04445.x

Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf). 2007;66(4):499-502. doi: 10.1111/j.1365-2265.2007.02758.x

Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165(4):509-15. doi: 10.1530/EJE-11-0304

Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92(5):1891- 6. doi: 10.1210/jc.2006-2513

Gadelha MR, Kasuki L, Korbonits M. The genetic background of acromegaly. Pituitary. 2017;20(1):10-21. doi: 10.1007/s11102-017- 0789-7

Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology. 2011;94(1):39-48. doi: 10.1159/000322787

Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escolá C, et al. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol. 2013;168(1):9-13. doi: 10.1530/EJE-12-0457

Ibáñez-Costa A, Korbonits M. AIP and the somatostatin system in pituitary tumours. J Endocrinol. 2017;235(3):R101-R16. doi: 10.1530/JOE-17-0254

Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012;97(8):E1411-20. doi: 10.1210/jc.2012-1111

Tong A, Jiang J, Wang F, Li C, Zhang Y, Wu X. Pure androgen- producing adrenal tumor: clinical features and pathogenesis. Endocr Pract. 2017;23(4):399-407. doi: 10.4158/EP161580.OR

Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K, Vahteristo P, et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer. 2007;96(2):352-6. doi: 10.1038/sj.bjc.6603573

Raitila A, Georgitsi M, Karhu A, Tuppurainen K, Mäkinen MJ, Birkenkamp-Demtröder K, et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer. 2007;14(3):901-6. doi: 10.1677/ERC-07-0025

Raitila A, Georgitsi M, Bonora E, Vargiolu M, Tuppurainen K, Mäkinen MJ, et al. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer. J Endocrinol Invest. 2009;32(5):426-9. doi: 10.1007/BF03346480

Magnusson L, Hansen N, Saba KH, Nilsson J, Fioretos T, Rissler P, et al. Loss of the tumour suppressor gene AIP mediates the browning of human brown fat tumours. J Pathol. 2017;243(2):160- 4. doi: 10.1002/path.4945

Pardi E, Marcocci C, Borsari S, Saponaro F, Torregrossa L, Tancredi M, et al. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2013;98(7):2800-10. doi: 10.1210/jc.2012-4029

Contadores